Long-term protection of macaques against high-dose type D retrovirus challenge after immunization with recombinant vaccinia virus expressing envelope glycoproteins.
Recombinant vaccinia virus expressing the envelope proteins of type D retrovirus-Washington (SRV-2/W) was used to immunize macaques against SRV-2 infection. Four immunized macaques which had resisted a prior low-dose challenge were rechallenged with a high dose (10(6) infectious particles) of SRV-2 two years after being immunized. All four non-immunized control macaques became infected, but the four vaccinated animals resisted this intravenous challenge, as determined by the inability to detect SRV-2 in peripheral blood mononuclear cells and by the lack of seroconversion to new viral antigens.
Benveniste
R E
RE
Laboratory of Viral Carcinogenesis, National Cancer Institute, Frederick Cancer Research and Development Center, MD.
Kuller
L
L
Roodman
S T
ST
Hu
S L
SL
Morton
W R
WR
D000818:Animals; D001483:Base Sequence; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D007114:Immunization; D015151:Immunoblotting; D008254:Macaca nemestrina; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D015301:Retroviruses, Simian / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000494:pharmacology; D014616:Vaccinia virus / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000494:pharmacology*
D004279:DNA, Viral; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines